At a glance
ClinicalIndex Comparison RecordPhase 2Active· 13 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Hodgkin Lymphoma and 2 related conditions. Active but no longer recruiting, targeting 13 participants across 4 sites.
Detailed Summary
This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: * Ipilimumab * Nivolumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2Active
20222023202420252026
Enrollment StartJun 2021
First PostedJun 2021
Primary CompletionApr 2024
TodayJul 2026
Study CompletionAug 2026
First PostedJun 24, 2021
Enrollment StartJun 4, 2021
Primary CompletionApr 1, 2024
Study CompletionAug 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.0 years ago
Interventions
Nivolumabdrug
Intravenous infusion
Ipilimumabdrug
Intravenous infusion